Prophylactic oral UFT therapy for superficial bladder cancer.

作者信息

Kubota Y, Hosaka M, Fukushima S, Kondo I

机构信息

Department of Urology, Yokohama City University, School of Medicine, Japan.

出版信息

Cancer. 1993 Mar 1;71(5):1842-5. doi: 10.1002/1097-0142(19930301)71:5<1842::aid-cncr2820710520>3.0.co;2-2.

BACKGROUND

A randomized prospective trial was performed to determine whether long-term oral UFT (a 1:4 mixture of tegafur and uracil) (Taiho Pharmaceutical Co., Tokyo, Japan) therapy was effective in preventing the intravesical recurrence of superficial bladder cancer.

METHODS

A total of 112 patients with newly diagnosed superficial transitional cell carcinoma of bladder (Ta, T1 and G1 or G2) were randomized into a UFT-treated group (300-400 mg/d for 2 years) and a control group.

RESULTS

After a median follow-up period of 24.5 months, the recurrence rate was 25.7% for the UFT group and 43.3% for the control group (P = 0.015, log-rank test). Side effects of UFT administration were acceptably low.

CONCLUSIONS

These results suggest that long-term UFT administration after transurethral resection is effective in preventing the recurrence of superficial bladder cancer.